Gross margin fell from 18.8% to 15.3% over the nine-month period.
Revenue declined 35.4% year-over-year for the nine months ended March 31, 2026.
Strategic pivot toward Malaysian manufacturing and biometric IP licensing.
Reclassified $35M of related-party debt to non-current with a 12-month deferment.
The latest 10-Q paints a picture of a company at a crossroads, balancing severe fundamental deterioration against high-conviction strategic pivots. The financial data confirms a shrinking core business, but the management's ability to slash OpEx and secure a unique manufacturing foothold in Malaysia suggests a disciplined attempt to survive. The primary tension for investors lies in whether the company can scale its Malaysian operations and monetize its IKE Tech IP before its remaining cash runway expires. Ultimately, the filing reveals a high-risk, high-reward scenario. The shift in FDA guidance regarding age-verification technology provides a tangible catalyst that could fundamentally re-rate the business. However, the reliance on related-party transactions and the volatility of the cannabis and nicotine regulatory environments maintain a high level of systemic risk. Investors are essentially betting on a race between the company's cash burn and the execution of its Malaysian and biometric technology milestones.